Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beijing Northland Biotech CoBJSE:920047 59 Gross Margin % is 44.68% as of Jun. 2026, which is 32% below its 10-year median of 65.85. GuruFocus rates BJSE:920047 with a GF Score™ of 59/100 and a GF Value™ of ¥15.45 (Fairly Valued). The stock has 7 warning signs investors should review. Among 737 Biotechnology companies, Beijing Northland Biotech Co ranks worse than 59.29% on this metric.
Beijing Northland Biotech Co (BJSE:920047) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Beijing Northland Biotech Co had a gross margin of 44.68% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Beijing Northland Biotech Co Gross Margin % Related Terms
Beijing Northland Biotech Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BJSE:920047 vs VRTX, REGN, MRNA: Gross Margin % Comparison
For the Biotechnology subindustry, Beijing Northland Biotech Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Northland Biotech Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beijing Northland Biotech Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Beijing Northland Biotech Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Beijing Northland Biotech Co (BJSE:920047) has a Gross Margin % of 44.68% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Beijing Northland Biotech Co and its competitors. This is 32% below median its historical median of 65.85. Over the past decade, Beijing Northland Biotech Co's Gross Margin % has ranged from 49.20 to 90.48. According to the industry distribution chart, Beijing Northland Biotech Co ranks #437 out of 737 companies in the Biotechnology industry, placing it in the top 59.3%.
Is Beijing Northland Biotech Co's Gross Margin % too high?
Beijing Northland Biotech Co's current Gross Margin % of 44.68% is 32% below median its 10-year median of 65.85. Over the past 10 years, this metric has ranged from a low of 49.20 to a high of 90.48. The Biotechnology industry median Gross Margin % is 60.91. Beijing Northland Biotech Co's value of 44.68% is 26.6% below this industry median. Based on the distribution chart, Beijing Northland Biotech Co ranks #437 out of 737 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Beijing Northland Biotech Co has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beijing Northland Biotech Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Northland Biotech Co ranks #437 out of 737 companies for Gross Margin %. This places Beijing Northland Biotech Co in the lower half of its industry. The industry median Gross Margin % is 60.91. Beijing Northland Biotech Co's value of 44.68% is 26.6% below this benchmark. Historically, Beijing Northland Biotech Co's own Gross Margin % has ranged from 49.20 to 90.48 over the past decade. While the company's 10-year median is 65.85 vs. the industry median of 60.91, Beijing Northland Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Northland Biotech Co's current Gross Margin % of 44.68% is 26.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Beijing Northland Biotech Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Northland Biotech Co's current Gross Margin % is 44.68%, which is 32% below median its own 10-year median of 65.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Northland Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Northland Biotech Co (BJSE:920047) is currently considered Fairly Valued. The stock's GF Value™ is ¥15.45, compared to a current price of ¥15.57 — trading 0.8% above its estimated fair value. The current Gross Margin % is 44.68%, which is 32% below median its 10-year median of 65.85 and 26.6% below the Biotechnology industry median of 60.91. Beijing Northland Biotech Co's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Beijing Northland Biotech Co (BJSE:920047), the current Gross Margin % is 44.68% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Northland Biotech Co (BJSE:920047) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Northland Biotech Co stock appears to be overvalued.
The current stock price of ¥15.57 is trading 0.8% above its estimated GF Value™ of ¥15.45.
GuruFocus considers Beijing Northland Biotech Co to be Fairly Valued.
Key valuation signals for BJSE:920047:
Gross Margin %: 44.68% (32% below median its 10-year median of 65.85)
GF Value™: ¥15.45 vs. price of ¥15.57 (0.8% above fair value)
Industry Position: 26.6% below the Biotechnology median (#437 of 737)
No single metric tells the full story. See the BJSE:920047 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Northland Biotech Co Ltd is engaged in technology transfer, technical services, production and sales of ophthalmic drugs, contract manufacturing, and contract research and development. The company's independently developed biopharmaceutical, NL003, has completed Phase III clinical trials this year.
59GF Score
Get the complete analysis for BJSE:920047
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920047 has been successfully added to your 
